榊原記念病院は、東京都府中市にある医療機関。公益財団法人日本心臓血圧研究振興会が運営する循環器専門の病院である。

During the past decade, Sakakibara Heart Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sakakibara Heart Institute" #1 sponsor was "Abbott Medical Devices" with 2 trials, followed by "Ministry of Health, Labour and Welfare, Japan" with 2 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored, "Boston Scientific Japan K.K." with 1 trials sponsored and "Cleerly, Inc." with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sakakibara Heart Institute" #1 collaborator was "Abbott" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "CellBank of Japan" with 1 trials as a collaborator, "Medtronic" with 1 trials as a collaborator and "Mitsubishi Tanabe Pharma Corporation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Sakakibara Heart Institute" are "Aortic Stenosis" (2 trials), "Aortic Valve Stenosis" (2 trials), "Heparin-Induced Thrombocytopenia" (2 trials), "Mitral Valve Regurgitation" (2 trials) and "Acute Heart Failure" (1 trials). Many other conditions were trialed in "Sakakibara Heart Institute" in a lesser frequency.

Most popular intervention types in "Sakakibara Heart Institute" are "Device" (9 trials), "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "17mm MDT-2215 aortic valve bioprosthesis" (1 trials), "AVJ-514" (1 trials), "BSJ003W" (1 trials), "Empagliflozin 10 MG" (1 trials) and "HS-001 CS" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sakakibara Heart Institute" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Sakakibara Heart Institute". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Sakakibara Heart Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Sakakibara Heart Institute, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".